Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mezigdomide and Elranatamab in Relapsed/Refractory Multiple Myeloma
NCT06645678Phase 2Recruiting
- Start
- Nov 2024
- Primary completion
- Oct 2026
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Bispecific Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of mezigdomide and elranatamab in multiple myeloma (MM). Primary endpoint: Overall Response Rate at 24 months. Started Nov 2024; status: recruiting.
02
Drugs
mezigdomideelranatamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06645678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06645678.